These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 10438394)
1. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. Abadi J; Pirofski La J Infect Dis; 1999 Sep; 180(3):915-9. PubMed ID: 10438394 [TBL] [Abstract][Full Text] [Related]
2. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Deshaw M; Pirofski LA Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565 [TBL] [Abstract][Full Text] [Related]
3. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice. Parra C; González JM; Castañeda E; Fiorentino S Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907 [TBL] [Abstract][Full Text] [Related]
4. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. Fleuridor R; Lyles RH; Pirofski L J Infect Dis; 1999 Nov; 180(5):1526-35. PubMed ID: 10515812 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Maitta RW; Datta K; Pirofski LA Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457 [TBL] [Abstract][Full Text] [Related]
6. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. Subramaniam K; French N; Pirofski LA Clin Diagn Lab Immunol; 2005 Oct; 12(10):1168-76. PubMed ID: 16210479 [TBL] [Abstract][Full Text] [Related]
7. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327 [TBL] [Abstract][Full Text] [Related]
8. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Zhang H; Zhong Z; Pirofski LA Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446 [TBL] [Abstract][Full Text] [Related]
9. Detection of IgM and IgG antibodies to Cryptococcus neoformans proteins in blood donors and HIV patients with active cryptococcosis. Chai HC; Tay ST Mycoses; 2009 Mar; 52(2):166-70. PubMed ID: 18643920 [TBL] [Abstract][Full Text] [Related]
10. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans]. Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590 [TBL] [Abstract][Full Text] [Related]
11. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Jalali Z; Ng L; Singh N; Pirofski LA Clin Vaccine Immunol; 2006 Jul; 13(7):740-6. PubMed ID: 16829610 [TBL] [Abstract][Full Text] [Related]
12. Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis. Saha DC; Xess I; Zeng WY; Goldman DL Med Mycol; 2008 Aug; 46(5):457-63. PubMed ID: 18608912 [TBL] [Abstract][Full Text] [Related]
13. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Houpt DC; Pfrommer GS; Young BJ; Larson TA; Kozel TR Infect Immun; 1994 Jul; 62(7):2857-64. PubMed ID: 8005676 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. Mukherjee J; Kozel TR; Casadevall A J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877 [TBL] [Abstract][Full Text] [Related]
15. A novel ELISA for determination of polysaccharide specific immunoglobulins. Spoljar BH; Tomasic J Vaccine; 2000 Nov; 19(7-8):924-30. PubMed ID: 11115717 [TBL] [Abstract][Full Text] [Related]
16. Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. Lamura L; Matthews RC; Barchiesi F; Donahoe M; Burnie JP; Scalise G J Infect; 2000 Jan; 40(1):64-8. PubMed ID: 10762114 [TBL] [Abstract][Full Text] [Related]
17. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097 [TBL] [Abstract][Full Text] [Related]
19. Serologic evidence for Cryptococcus neoformans infection in early childhood. Goldman DL; Khine H; Abadi J; Lindenberg DJ; Pirofski La ; Niang R; Casadevall A Pediatrics; 2001 May; 107(5):E66. PubMed ID: 11331716 [TBL] [Abstract][Full Text] [Related]
20. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Pirofski LA Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]